No headlines found.
Globe Newswire (Wed, 12-Nov 4:05 PM ET)
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.
Korro Bio trades on the NASDAQ stock market under the symbol KRRO.
As of December 8, 2025, KRRO stock price climbed to $7.52 with 361,614 million shares trading.
KRRO has a beta of 1.93, meaning it tends to be more sensitive to market movements. KRRO has a correlation of 0.03 to the broad based SPY ETF.
KRRO has a market cap of $70.82 million. This is considered a Micro Cap stock.
Last quarter Korro Bio reported $1 million in Revenue and -$1.92 earnings per share. This beat revenue expectation by $243,064 and exceeded earnings estimates by $.73.
The top ETF exchange traded funds that KRRO belongs to (by Net Assets): VTI, VXF, VTWO, IWM, VHT.
KRRO has underperformed the market in the last year with a return of -80.8%, while the SPY ETF gained +13.8%. In the last 3 month period, KRRO fell short of the market, returning -77.3%, while SPY returned +5.8%. However, in the most recent 2 weeks KRRO has outperformed the stock market by returning +19.7%, while SPY returned +3.6%.
KRRO support price is $6.52 and resistance is $7.52 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that KRRO shares will trade within this expected range on the day.
